Congratulations to Hanmi Pharmaceutical Co., Ltd.

ProSciento is proud to support the clinical research and development activities of Hanmi Pharmaceuticals and congratulate Hanmi and Sanofi on their partnership to develop therapeutics addressing diabetes.

The licensing agreement announced by Sanofi and Hanmi Pharmaceuticals represents the intent to develop and commercialize Hanmi’s portfolio of three long-acting GLP-1 agonist and basal insulin candidates, including efpeglenatide, a phase 2b GLP-1 agonist with the potential for once-weekly to once-monthly dosing; LAPSInsulin-115, a phase 1 once-weekly insulin; and LAPSInsulin Combo, a preclinical once-weekly fixed-ratio GLP-1 agonist/basal insulin combination of efpeglenatide and LAPSInsulin-115. The three candidates were developed using Hanmi’s proprietary LAPSCOVERY technology.

According to the press release, Sanofi will provide Hanmi with an upfront payment of €400 million (~$434 million). Hanmi will also be eligible for up to €3.5 billion (~$3.8 billion) based on development, registration, and sales milestones and will earn double-digit royalties on net sales of the products. While Sanofi gains worldwide commercialization rights, Hanmi will retain an exclusive option to co-commercialize the products in South Korea and China.

ProSciento and Hanmi have jointly presented data at the American Diabetes Association (ADA) Scientific Sessions and European Association for the Study of Diabetes (EASD) Annual Meetings since 2013. Below are links to abstracts related to the three long-acting GLP-1 agonist and basal insulin candidates and presented at the most recent ADA Scientific Sessions.

96-OR – Unique Profile of the Weekly Insulin HM12470: Very Slow Onset of Action, Rapid Off-Rate Similar to Insulin, and Absence of Insulin Receptor Downregulation

105-LB – Once-a-Month Treatment with HM11260C Improves Glycemic Control in Type 2 Diabetes (T2DM)—Interim Data from a 16-Week Study

172-OR – Once-Weekly Combination of GLP-1R Agonist and Insulin (HM14220) Offers Improved Glycemic Control and Reduced Weight Gain Risk

278-OR – Dose-Response Improvements in Glycemic Control and Body Weight Reductions with HM11260C, a Once-Weekly GLP-1 Receptor Agonist with Liraglutide as Reference, in Type 2 Diabetes (T2DM)

303-LB – Significant Effects of HM11260C on Body Weight over 20 Weeks in Obese Subjects without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Study

1116-P – SuperagonisticMechanism of Increased Glucodynamic and Weight Loss Effects of LAPSCA-Exendin-4 (HM11260C)

1123-P – LAPS-Exendin-4 (HM11260C) Significantly Enhances Insulin Secretion and ß-Cell Responsiveness in Subjects with Type 2 Diabetes Mellitus (T2DM)

2561-PO – Noninferior Delay in Gastric Emptying vs. Liraglutide and Favorable Glucometabolic Profile following Treatment with LAPSExendin-4 (HM11260C) in Subjects with Type 2 Diabetes Mellitus (T2DM)